Wednesday, October 2, 2024

CVS is rumored to be weighing breaking up its retail and insurance businesses amid investor pressure. Johnson & Johnson is abandoning its controversial 340B drug discount rebate plan.  And, The Biden Administration is no longer pursuing its push for greater Medicaid drug price transparency, according to a report.  We’ll get that story--and more--coming up on today’s episode of the Gist Healthcare podcast.  Hosted on Acast. See acast.com/privacy for more information.